FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
Fortress Biotech, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.87+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $59.45M
- P/E (TTM)
- –
- Dividend yield
- –
Fortress Biotech statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Fortress Biotech | Industry median |
|---|---|---|
| Market Cap | $68.78M | $164.85M |
| Enterprise Value | -$51.25M | $87.06M |
| PS Ratio | 1.00 | 3.60 |
| PB Ratio | 0.42 | 2.03 |
| P/TBV Ratio | 0.50 | 2.31 |
| P/OCF Ratio | 0.55 | 13.32 |
Enterprise value
| Measure | Fortress Biotech | Industry median |
|---|---|---|
| EV / Sales | -0.75 | 2.43 |
Income (trailing twelve months)
| Measure | Fortress Biotech | Industry median |
|---|---|---|
| Revenue | $68.47M | $57.94M |
| Gross Profit | $44.91M | $90.47M |
| Operating Income | -$29.35M | -$21.44M |
| Pretax Income | $145.86M | -$14.45M |
| Net Income | $111.82M | -$22.46M |
| EBITDA | -$29.35M | -$16.91M |
Margins
| Measure | Fortress Biotech | Industry median |
|---|---|---|
| Gross Margin | 65.6% | 52.3% |
| Operating Margin | -42.9% | -44.5% |
| Pretax Margin | 213.0% | -13.0% |
| Profit Margin | 163.3% | -39.2% |
| EBITDA Margin | -42.9% | -31.3% |
Returns
| Measure | Fortress Biotech | Industry median |
|---|---|---|
| Return on Equity (ROE) | 107.5% | -53.1% |
| Return on Assets (ROA) | 46.9% | -41.0% |
| Return on Invested Capital (ROIC) | -261.5% | -32.0% |
| Return on Capital Employed (ROCE) | -11.5% | -37.8% |
Growth
| Measure | Fortress Biotech | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 15.5% | 6.01% |
| Revenue Growth (3Y CAGR) | -5.83% | 2.25% |
| Revenue Growth (5Y CAGR) | 6.77% | 6.42% |
Balance sheet
| Measure | Fortress Biotech | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $196.58M | $62.42M |
| Total Debt | $34.60M | $120.13M |
| Net Cash (Debt) | $161.97M | $15.68M |
| Net Cash Per Share | $4.40 | $0.66 |
| Equity (Book Value) | $164.14M | $48.79M |
| Book Value Per Share | $4.46 | $1.36 |
| Tangible Book Value | $138.63M | $23.06M |
| Working Capital | $183.49M | $75.77M |
Financial position
| Measure | Fortress Biotech | Industry median |
|---|---|---|
| Current Ratio | 3.96 | 3.30 |
| Quick Ratio | 3.75 | 2.39 |
| Debt / Equity | 0.21 | 0.51 |
| Interest Coverage | -3.05 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Fortress Biotech | Industry median |
|---|---|---|
| Operating Cash Flow | $125.92M | -$12.35M |
Efficiency
| Measure | Fortress Biotech | Industry median |
|---|---|---|
| Asset Turnover | 0.29 | 0.38 |
| Inventory Turnover | 2.24 | 2.67 |
| Revenue Per Employee | $877.77K | $398.96K |
| Profits Per Employee | $1.43M | -$703.34K |
| Employee Count | 78 | 74 |
Dividends and yields
| Measure | Fortress Biotech | Industry median |
|---|---|---|
| Earnings Yield | 162.6% | -22.7% |
Shares
| Measure | Fortress Biotech | Industry median |
|---|---|---|
| Shares Outstanding | 36,778,100 | 58,179,650 |
| Shares Change (YoY) | 20.4% | 11.1% |
| Shares Change (QoQ) | 0.37% | 0.54% |
| Float | 25,145,800 | 49,173,100 |
| Shares Held by Insiders | 31.6% | 11.6% |
| Shares Held by Institutions | 15.9% | 59.4% |
Taxes
| Measure | Fortress Biotech | Industry median |
|---|---|---|
| Income Tax | $4.66M | $91.50K |
| Effective Tax Rate | 3.20% | 20.6% |
Scores
| Measure | Fortress Biotech | Industry median |
|---|---|---|
| Altman Z-Score | -1.78 | -0.24 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from Fortress Biotech's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.